News

Latest News News

PanEcho: AI-Based Automated Image Analysis Improved Quality and Efficiency in Echocardiography

Key Points: Transthoracic echocardiography is foundational to diagnosis and evaluation of myriad…

Leah Kosyakovsky

TOPSPIN- A: Three-Combination of Antihypertensive Meds Provided Similar BP Control

Key Points: The global burden of hypertension (HTN) with high globally at…

Leah Kosyakovsky

Personalized App-Based Coaching Improved Physical Activity in HFpEF Patients (MyoMobile Study)

Key Points: Though physical inactivity leads to poor cardiovascular outcomes, especially for…

Leah Kosyakovsky

ZODIAC: A Risk-based Decision Support System Did Not Significantly Improve Lipid-Lowering vs Usual Care

Key Points Maximizing lipid lowering therapy (LLTs) to optimize residual cardiovascular disease…

Leah Kosyakovsky

Exenatide, a GLP-1 Analog, Did Not Reduce Organ Injury, Stroke or Death During Cardiac Surgery: GLORIOUS Trial

KEY POINTS: Exenatide is a glucaon-like-peptide-1 agonist (GLP-1) improves glycemic control, and…

Leah Kosyakovsky

Plozasiran Showed Sustained Reductions in TG in Familial Chylomicronemia Syndrome: PALISADE Trial

Key Points: Familial chylomicronemia syndrome (FCS) is characterized by extremely high plasma…

Leah Kosyakovsky

Catheter Ablation Better Than Antiarrhythmic Drugs for VT in Ischemic Cardiomyopathy With ICD: VANISH2 Trial

Key Takeaways: The VANISH2 trial compared catheter ablation with systematic antiarrhythmic drug…

Leah Kosyakovsky

CLEAR SYNERGY: No Benefit with Routine Spironolactone in MI Patients

Key Takeaways: The CLEAR SYNERGY trial was a multicenter trial with a…

Leah Kosyakovsky

CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran Associated with Durable Reductions in Serum TTR levels for ATTR -CM

Key Takeaways: A single dose of nexiguran ziclumeran (nex-z), a CRISPR-Cas9-based therapy,…

Leah Kosyakovsky

SUMMIT: Tirzepatide Decreased The Risk Of Worsening HF And CV Death in HFpEF + Obesity

Key Points SUMMIT was a multi-national trial that compared cardiovascular outcomes among…

Leah Kosyakovsky

BPROAD: Intensive Blood Pressure Target Reduces MACE in Type 2 Diabetes

Key Points BPROAD was a randomized control trial in China that assigned…

Leah Kosyakovsky

Rivaroxaban Did Not Reduce Cognitive Decline and Stroke/TIA in Young AF Patients: BRAIN-AF Trial

Key Points: In patients with atrial fibrillation, it remains unclear if anticoagulation…

Leah Kosyakovsky

QFR Did Not Meet Non-inferiority to FFR: FAVOR III Europe Trial

The FAVOR III Europe study aimed to investigate whether a QFR-based diagnostic…

Leah Kosyakovsky

Orbital Atherectomy No Benefit Over Conventional Ballon Dilatation in Calcified Lesions: ECLIPSE Trial

The ECLIPSE trial evaluated orbital atherectomy (OA) vs conventional balloon dilatation (BA)…

Leah Kosyakovsky

No Benefit of Colchicine in Large MIs: CLEAR SYNERGY Trial

Several randomized trials have shown reductions in MACE with colchicine in the…

Leah Kosyakovsky

ApoA-I Infusions and Burden of Ischemic Events after Acute Myocardial Infarction

KEY POINTS:  In this prespecified exploratory analysis of the AEGIS-II trial, the…

Leah Kosyakovsky

Apolipoprotein A-I infusions Lowers Risk of Recurrent CV Events in Patients With Baseline LDL-C ≥100 mg/dL

KEY POINTS: In this exploratory analysis of the AEGIS-II randomized control trial,…

Leah Kosyakovsky

Improved Accuracy of HF Diagnosis with HFDetect-AI

Key Points: HFDetect-AI significantly improves the accuracy of diagnosing heart failure by…

Leah Kosyakovsky

Pre-Hospital Pulse-Dose Glucocorticoid Did not Reduce Infarct Size in STEMI: PULSE-MI

Key Points: The PULSE-MI trial assessed the effects of pre-hospital pulse-dose glucocorticoid…

Leah Kosyakovsky

ECLS-SHOCK: At One Year, ECMO Does Not Reduce Mortality in Acute MI-Related Cardiogenic Shock

Key Points: The 30-day ECLS SHOCK study demonstrated no benefit to up-front…

Leah Kosyakovsky